TLDR: Regulatory affairs converts science into market access, which makes it structurally necessary rather than discretionary. Demand across the EU and US in 2026 outpaces supply, and the specialists who combine one deep framework with a working second command the strongest positions.
Regulatory affairs owns the path to market, which is why the function survives cost cuts
A medicine or device that cannot be lawfully sold generates nothing, whatever its scientific merit. Regulatory affairs is the function that closes that gap: it assembles the argument that a product is safe, effective and manufactured under control, presents it to the authorities in the form they require, and maintains that authorisation for the rest of the product’s commercial life. Because the function sits directly on the revenue path rather than beside it, it behaves very differently from support roles when budgets tighten.
The daily work is more varied than the job title suggests. Regulatory professionals compile submission dossiers from clinical, non-clinical and manufacturing data, interpret guidance that shifts faster than any textbook can follow, and negotiate directly with assessors who question the evidence. They manage the constant stream of post-approval changes — a new manufacturing site, a revised specification, an updated safety signal — each of which requires its own filing. They also police what the commercial organisation may claim, since labelling and promotional boundaries derive from the approved dossier rather than from marketing preference.
Resilience follows from the structure of the obligation rather than from sentiment about the profession. Regulatory work is mandatory and continuous: a company that pauses hiring can defer a marketing campaign or slow a research programme, but it cannot stop filing variations, responding to authority questions or maintaining safety reporting without putting existing authorisations at risk. Even a portfolio in decline generates regulatory workload, and a company being acquired generates a great deal of it. That asymmetry is what makes the track relatively insulated from cycles.
The same logic explains the seniority the function has gained. Regulatory strategy now shapes decisions taken years before a submission — which indication to pursue, which comparator to use, which markets to enter first — because those choices determine what can eventually be claimed. Heads of regulatory sit on development committees for that reason, and the route from specialist to executive is shorter here than in most scientific functions. Understanding where the demand concentrates is the practical starting point.
Five role families carry most of the 2026 demand, and they are not equally hard to fill
Regulatory affairs is a collection of specialisms rather than a single career, and the shortage is concentrated in particular corners of it rather than spread evenly across the function. Two candidates with identical years of experience can face very different markets depending on which corner they occupy, and the gap widens as seniority increases. Independent 2026 market analysis points to acute, persistent shortages in regulatory affairs, driven by the MDR and IVDR transition and by the dual Swissmedic and EMA requirements Swiss-based companies carry. Choosing where to position yourself within the function matters more than choosing the function itself.
The Regulatory Affairs Manager or Specialist is the core role and the one most people recognise. The holder owns submissions and authority interactions for a product or a region, coordinates the contributors who supply the underlying data, and carries responsibility for the timeline. It is the position from which most regulatory careers branch, because it exposes the holder to the full submission lifecycle rather than to one slice of it. Employers recruit for it continuously, and candidates with experience of a completed submission from planning through to approval are consistently preferred.
Regulatory CMC — chemistry, manufacturing and controls — is among the hardest specialisms to fill anywhere in the industry. The work links the physical reality of manufacturing to the dossier that describes it, which demands genuine process chemistry or biologics understanding alongside regulatory skill. That dual requirement is precisely why the pool is small: the training path runs through manufacturing or analytical development rather than through a regulatory qualification alone, so the supply cannot be expanded quickly. Scarcity of this kind translates directly into negotiating position.
Three further families complete the picture. MedTech regulatory specialists take devices and diagnostics through a European regime that now demands clinical evidence where technical documentation once sufficed. Regulatory intelligence and strategy professionals anticipate change and design submission plans across jurisdictions, a role that rewards judgement over procedure. Pharmacovigilance and safety sits adjacent, tracks the same shortage, and offers a natural lateral move for anyone whose interest runs to signal detection and benefit-risk. Where you sit among these families shapes which regulator you will spend your career arguing with.
| Role family | What it owns | Typical entry route |
|---|---|---|
| RA Manager / Specialist | Submissions and authority interactions for a product or region | Quality, clinical operations or lab science plus a regulatory qualification |
| Regulatory CMC | The manufacturing and controls sections of the dossier | Process chemistry, analytical development or biologics manufacturing |
| MedTech regulatory (MDR / IVDR) | Technical documentation and clinical evidence for devices and diagnostics | Device engineering, quality assurance or notified body experience |
| Regulatory intelligence and strategy | Cross-jurisdiction submission strategy and horizon scanning | Progression from a specialist role, often after a first approval |
| Pharmacovigilance and safety | Signal detection, benefit-risk and safety reporting | Clinical, pharmacy or medical background |
Europe and the United States reward different instincts, and dual fluency pays most
The two largest regulated markets solve the same problem with different architectures, and the difference runs considerably deeper than terminology. Europe distributes authority across a network of agencies, member states and private assessment bodies; the United States concentrates it in a single federal agency with defined procedural gates. Those structures produce different working habits, different negotiating rhythms and different definitions of what counts as sufficient evidence. A professional trained in one system meets genuine friction on first contact with the other, which is exactly why people fluent in both are valued so highly by companies selling across the Atlantic.
In Europe, the centralised procedure run through the European Medicines Agency coexists with national and mutual-recognition routes, and the choice between them is itself a strategic decision with consequences for timing and market coverage. Devices follow an entirely separate logic, assessed by private notified bodies under the MDR and IVDR rather than by a public agency, which makes notified body capacity and relationship management part of the job. Swissmedic operates alongside this as a sovereign authority, so Swiss-based companies routinely run parallel processes and Swiss-based professionals develop multi-authority fluency as a matter of course.
The United States Food and Drug Administration presents a single counterparty and a set of defined pathways: IND, NDA and BLA for therapeutics, and 510(k), De Novo and PMA for devices. The culture is more interactive than many European professionals expect, with formal meetings at defined development milestones where a sponsor can test its approach before committing to it. That interactivity is a real skill: getting value from an agency meeting requires knowing which questions to ask and how to frame them, and it rewards preparation in a way that written procedure does not.
Building the second fluency is more achievable than it looks from inside the first. Volunteering for the American or European workstream of a global submission, joining a regulatory intelligence group covering the other region, or taking a role at a company whose lead market differs from your current one all deliver genuine exposure. Switzerland is a particularly efficient place to develop it, because the density of globally selling companies means transatlantic filings are ordinary work. What travels between systems is less the procedural knowledge than the underlying craft.
The skills that raise your value are argumentative rather than encyclopaedic
Regulations are published and searchable, so knowing them is table stakes rather than differentiation, and any candidate can arrive at an interview able to recite the relevant framework. What separates a competent regulatory professional from an expensive one is the ability to construct a persuasive case from imperfect evidence and defend it under expert challenge from people who assess such cases for a living. A dossier is an argument, and assessors read it as one. The discipline that raises your market value most is therefore the discipline of reasoning clearly in writing.
Depth in one framework with working knowledge of a second is the pattern employers actively seek. Deep knowledge means having worked a full cycle inside it — planning, compiling, responding to questions, securing the outcome — rather than having read the guidance. Working knowledge of a second means being able to identify where the two regimes diverge and flag the consequence early, which is what allows a global programme to avoid designing itself into a corner. That combination is rarer than either component alone, and it is the profile that commands premium offers.
Project management is the underrated half of the role and often the reason submissions slip. A regulatory lead coordinates statisticians, manufacturing colleagues, clinical teams and external partners who report elsewhere, against a deadline that is frequently fixed by a commercial commitment. Influence without authority is therefore a daily requirement, and the people who do it well tend to be the ones who make the dependencies visible early rather than chasing contributors late. Employers assess this directly, so prepare examples of how you kept a complex timeline intact.
Digital capability increasingly separates candidates at the same experience level. Structured submission formats, regulatory information management systems and AI-assisted tools for guidance review and document drafting are becoming standard equipment, and professionals who use them well handle more scope with the same effort. The judgement about what a submission should argue remains human, which is precisely why the combination of tooling fluency and regulatory reasoning is so valuable. Both can be built deliberately, which brings the question round to how people actually get in.
Entering from an adjacent function works when you engineer exposure to a real submission
Most regulatory professionals arrive from somewhere else, and the function is unusually open to lateral entry as a result. Quality assurance, clinical operations, laboratory science, medical writing and manufacturing all supply candidates who already understand how regulated evidence is generated and why its provenance matters. The transferable asset is credibility with the data itself, since someone who has run the assay or managed the trial knows what the numbers can and cannot support. The missing piece is procedural knowledge, and that is much the easier of the two to acquire.
The most effective route pairs a formal qualification with engineered internal exposure. A regulatory certificate or diploma signals intent and supplies vocabulary, but hiring managers weigh contribution to an actual filing far more heavily. Volunteering to author a section of a dossier, joining a submission team as a subject-matter contributor, or taking responsibility for a variation in your current role converts a career ambition into evidence. Internal moves are often the shortest path for exactly this reason: your employer already knows your work and can take a risk an external recruiter cannot.
For those already inside the function, specialisation is the fastest way to raise market value. Moving towards CMC, MedTech under the European device regime, or dual transatlantic strategy positions you where the shortage is deepest rather than where competition is thickest. The move usually requires accepting a stretch assignment before you feel ready, since these skills are built on live programmes rather than in training rooms. Employers facing an unfilled specialist vacancy are frequently willing to support that stretch.
Structured learning sharpens the strategic judgement that senior regulatory roles reward, particularly the shift from executing submissions competently to influencing which submissions are worth making at all. That transition is where many technically excellent specialists stall, because the skills involved are commercial and persuasive rather than procedural. Edward Galle candidates can access HBR-backed training journeys designed for exactly that step. The final variable is visibility: specialist roles at this level are frequently filled through professional networks well before they ever reach a job board.
Edward Galle recruits regulatory and life-sciences specialists for employers across Switzerland, the EU and the US. Submit your CV for a confidential review, or talk to our team about where your framework experience would be worth most.
References
- Panda International. Swiss Life Sciences Hiring Trends for 2026. https://www.panda-int.com/en-ch/insights/swiss-life-sciences-hiring-trends-for-2026/
- European Medicines Agency. https://www.ema.europa.eu/en
- U.S. Food and Drug Administration. https://www.fda.gov/
